Literature DB >> 28391609

HPV testing in first-void urine provides sensitivity for CIN2+ detection comparable with a smear taken by a clinician or a brush-based self-sample: cross-sectional data from a triage population.

A Leeman1, M Del Pino2, A Molijn1, A Rodriguez2, A Torné2, M de Koning1, J Ordi3, F van Kemenade4, D Jenkins1, W Quint1.   

Abstract

OBJECTIVE: To compare the sensitivity of high-risk human papillomavirus (hrHPV) and genotype detection in self-collected urine samples in the morning (U1), and later on (U2), brush-based self-samples (SS), and clinician-taken smears (CTS) for detecting cervical intraepithelial neoplasia grade 2+ (CIN2+) in a colposcopic referral population.
DESIGN: Cross-sectional single-centre study.
SETTING: A colposcopy clinic in Spain. POPULATION: A cohort of 113 women referred for colposcopy after an abnormal Pap smear.
METHODS: Women undergoing colposcopy with biopsy for abnormal Pap smears were sent a device (Colli-Pee™, Novosanis, Wijnegem, Belgium) to collect U1 on the morning of colposcopy. U2, CTS, and SS (Evalyn brush™, Rovers Medical Devices B.V., Oss, the Netherlands) were also analysed. All samples were tested for HPV DNA using the analytically sensitive SPF10-DEIA-LiPA25 assay and the clinically validated GP5+/6+-EIA-LMNX. MAIN OUTCOME MEASURES: Histologically confirmed CIN2+ and hrHPV positivity for 14 high-risk HPV types.
RESULTS: Samples from 91 patients were analysed. All CIN3 cases (n = 6) tested positive for hrHPV in CTS, SS, U1, and U2 with both HPV assays. Sensitivity for CIN2+ with the SPF10 system was 100, 100, 95, and 100%, respectively. With the GP5+/6+ assay, sensitivity was 95% in all sample types. The sensitivities and specificities for both tests on each of the sample types did not significantly differ. There was 10-14% discordance on hrHPV genotype.
CONCLUSIONS: CIN2+ detection using HPV testing of U1 shows a sensitivity similar to that of CTS or brush-based SS, and is convenient. There was substantial to almost excellent agreement between all samples on genotype with both hrHPV assays. There was no advantage in testing U1 compared with U2 samples. TWEETABLE ABSTRACT: Similar CIN2+ sensitivity for HPV testing in first-void urine, physician-taken smear and brush-based self-sample.
© 2017 Royal College of Obstetricians and Gynaecologists.

Entities:  

Keywords:  Cervical intraepithelial neoplasia; human papillomavirus; self-sampling; urine

Mesh:

Substances:

Year:  2017        PMID: 28391609     DOI: 10.1111/1471-0528.14682

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  18 in total

1.  Racial and Ethnic Differences in Acceptability of Urine and Cervico-Vaginal Sample Self-Collection for HPV-Based Cervical Cancer Screening.

Authors:  Eliane Rohner; F Hunter McGuire; Yutong Liu; Quefeng Li; Kate Miele; Samveg A Desai; John W Schmitt; Andrea Knittel; Julie A E Nelson; Claire Edelman; Vijay Sivaraman; Anna Baker; LaHoma S Romocki; Lisa Rahangdale; Jennifer S Smith
Journal:  J Womens Health (Larchmt)       Date:  2020-03-26       Impact factor: 2.681

2.  Test Accuracy of Human Papillomavirus in Urine for Detection of Cervical Intraepithelial Neoplasia.

Authors:  Eliane Rohner; Lisa Rahangdale; Busola Sanusi; Andrea K Knittel; Laurence Vaughan; Kirsty Chesko; Brian Faherty; Samantha E Tulenko; John W Schmitt; LaHoma S Romocki; Vijay Sivaraman; Julie A E Nelson; Jennifer S Smith
Journal:  J Clin Microbiol       Date:  2020-02-24       Impact factor: 5.948

3.  A Randomized Comparison of Different Vaginal Self-sampling Devices and Urine for Human Papillomavirus Testing-Predictors 5.1.

Authors:  Louise Cadman; Caroline Reuter; Mark Jitlal; Michelle Kleeman; Janet Austin; Tony Hollingworth; Anna L Parberry; Lesley Ashdown-Barr; Deepali Patel; Belinda Nedjai; Attila T Lorincz; Jack Cuzick
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-01-29       Impact factor: 4.254

4.  Triage of human papillomavirus infected women by methylation analysis in first-void urine.

Authors:  Severien Van Keer; Annina P van Splunter; Jade Pattyn; Annemie De Smet; Sereina A Herzog; Xaveer Van Ostade; Wiebren A A Tjalma; Margareta Ieven; Pierre Van Damme; Renske D M Steenbergen; Alex Vorsters
Journal:  Sci Rep       Date:  2021-04-12       Impact factor: 4.379

Review 5.  Candidate biomarkers in the cervical vaginal fluid for the (self-)diagnosis of cervical precancer.

Authors:  Xaveer Van Ostade; Martin Dom; Wiebren Tjalma; Geert Van Raemdonck
Journal:  Arch Gynecol Obstet       Date:  2017-11-15       Impact factor: 2.344

6.  Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses.

Authors:  Marc Arbyn; Sara B Smith; Sarah Temin; Farhana Sultana; Philip Castle
Journal:  BMJ       Date:  2018-12-05

7.  Detection of high-risk human papillomavirus RNA in urine for cervical cancer screening with HPV 16 & 18/45 genotyping.

Authors:  Radha Rani Padhy; Adi Davidov; Louise Madrigal; Gina Alcide; Almir Spahiu
Journal:  Heliyon       Date:  2020-04-22

8.  Performance of an affordable urine self-sampling method for human papillomavirus detection in Mexican women.

Authors:  Rubí Hernández-López; Luis Hermosillo; Leith León-Maldonado; Rafael Velázquez-Cruz; Leticia Torres-Ibarra; Eduardo Lazcano-Ponce; Attila Lörincz; Cosette M Wheeler; F Xavier Bosch; Jack Cuzick; Berenice Rivera-Paredez; Belinda Nedjai; Jorge Salmerón
Journal:  PLoS One       Date:  2021-07-21       Impact factor: 3.240

9.  Human papillomavirus genotype and viral load agreement between paired first-void urine and clinician-collected cervical samples.

Authors:  Severien Van Keer; Wiebren A A Tjalma; Jade Pattyn; Samantha Biesmans; Zoë Pieters; Xaveer Van Ostade; Margareta Ieven; Pierre Van Damme; Alex Vorsters
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-02-07       Impact factor: 3.267

10.  Methylation analysis in urine fractions for optimal CIN3 and cervical cancer detection.

Authors:  Rianne van den Helder; Nienke E van Trommel; Annina P van Splunter; Birgit I Lissenberg-Witte; Maaike C G Bleeker; Renske D M Steenbergen
Journal:  Papillomavirus Res       Date:  2020-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.